Diamonds and Dogs


Merck pushing the Dow back toward 20,000. Merck (MRK) is up 5% after receiving FDA acceptance of supplemental biologics license application for Keytruda in combo with chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer. Analysts believe the market for first-line lung cancer for all patients could be as high as $14 billion. Rival, Bristol is down 3% on this news.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.